



February 21, 2023

Listing Department

**Code: 531335**

**BSE LIMITED**

P. J. Towers, Dalal Street,  
Mumbai-400 001

Sub: **Revised Outcome of Board meeting**

Dear Sir / Madam,

Please find attached herewith the revised unaudited financial results (standalone and consolidated) for the quarter and nine months ended on December 31, 2022, submitted to the Stock Exchanges on February 2, 2023.

Below is the revision in the unaudited financial results:

On the right side of the results, in the heading, the word "Company" has been replaced by the word "Standalone".

We request you to take the same on your records.

Thanking you,

Yours faithfully,

For, **ZYDUS WELLNESS LIMITED**

**NANDISH P. JOSHI**

**COMPANY SECRETARY**

**Encl.:** As above

**Zydus Wellness Limited**

(a subsidiary of Zydus Lifesciences Limited)

**Regd. Office:** 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad – 382481, India.

**Phone No.:** +91-79-71800000; **Website:** [www.zyduswellness.com](http://www.zyduswellness.com)

**CIN:** L15201GJ1994PLC023490

**Statement of Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2022**

₹ in Lakhs						Sr. No.	Particulars	₹ in Lakhs					
CONSOLIDATED								STANDALONE					
Quarter Ended		Nine Months Ended		Year Ended				Quarter Ended		Nine Months Ended		Year Ended	
December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022	December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022		
[Unaudited]						[Unaudited]							
[Audited]						[Audited]							
						1	<b>Income</b>						
						a	Revenue from operations						
41,296	42,677	38,493	1,53,271	1,35,327	1,98,846	i	Sales	5,523	5,920	6,194	16,841	13,646	19,042
262	270	316	910	1,605	2,064	ii	Other operating income	849	802	892	2,433	1,936	2,583
41,558	42,947	38,809	1,54,181	1,36,932	2,00,910		<b>Total Revenue from operations</b>	6,372	6,722	7,086	19,274	15,582	21,625
84	135	269	414	844	1,040	b	Other income	334	289	370	994	1,185	1,540
41,642	43,082	39,078	1,54,595	1,37,776	2,01,950		<b>Total Income</b>	6,706	7,011	7,456	20,268	16,767	23,165
						2	<b>Expenses</b>						
						a	Cost of materials consumed	4,227	4,320	3,902	12,698	10,359	14,589
26,603	20,916	21,432	72,531	54,620	88,494	b	Purchases of stock-in-trade	-	-	-	-	-	-
1,478	1,376	837	6,108	4,890	9,463	c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(138)	139	704	84	699	654
(4,757)	2,057	(2,196)	895	7,085	80	d	Employee benefits expense	619	806	796	2,171	2,528	3,106
3,509	4,363	3,820	12,381	12,349	16,356	e	Finance costs	55	1	54	101	153	202
384	294	642	1,092	1,953	2,551	f	Depreciation and amortisation expense	74	106	70	252	207	284
588	643	584	1,835	1,754	2,362	g	Advertisement and promotion expense	-	-	222	-	651	1,093
4,426	5,169	5,317	19,212	16,991	23,475	h	Other expenses	429	208	452	1,296	2,241	2,715
7,480	7,440	6,370	23,797	20,672	28,567		<b>Total expenses</b>	5,266	5,580	6,200	16,602	16,838	22,643
39,711	42,258	36,806	1,37,851	1,20,314	1,71,348	3	<b>Profit/ [Loss] before exceptional items and tax [1-2]</b>	1,440	1,431	1,256	3,666	(71)	522
1,931	824	2,272	16,744	17,462	30,602	4	Exceptional items [Refer Note 4]	-	-	-	-	-	-
-	-	-	291	-	-	5	<b>Profit/ [Loss] before tax [3-4]</b>	1,440	1,431	1,256	3,666	(71)	522
1,931	824	2,272	16,453	17,462	30,602	6	<b>Tax expense</b>						
-	-	-	-	-	-	a	Current tax	-	-	-	-	-	-
(25)	(23)	(58)	(51)	(95)	(285)	b	Deferred tax	(63)	(47)	-	(110)	-	(748)
(25)	(23)	(58)	(51)	(95)	(285)		<b>Total tax expenses</b>	(63)	(47)	-	(110)	-	(748)
1,956	847	2,330	16,504	17,557	30,887	7	<b>Net Profit/ [Loss] [5-6]</b>	1,503	1,478	1,256	3,776	(71)	1,270
						8	<b>Other Comprehensive Income [OCI]</b>						
(7)	(17)	(125)	(49)	(377)	(101)	a	Items that will not be reclassified to profit or loss [net of tax]	(8)	(74)	(11)	(81)	(34)	1
-	8	-	28	7	20	b	Items that will be reclassified to profit or loss [net of tax]	-	-	-	-	-	-
(7)	(9)	(125)	(21)	(370)	(81)		<b>Total Other Comprehensive Income [net of tax]</b>	(8)	(74)	(11)	(81)	(34)	1
1,949	838	2,205	16,483	17,187	30,806	9	<b>Total Comprehensive Income [7+8]</b>	1,495	1,404	1,245	3,695	(105)	1,271
						10	<b>Total Comprehensive Income attributable to:</b>						
1,949	838	2,205	16,483	17,187	30,806	a	Owners of the company	1,495	1,404	1,245	3,695	(105)	1,271
6,363	6,363	6,363	6,363	6,363	6,363	11	Paid-up equity share capital [Face Value ₹ 10 each]	6,363	6,363	6,363	6,363	6,363	6,363
					4,78,040	12	Reserve excluding Revaluation Reserve						3,93,655
						13	<b>Earnings per share [EPS]</b>						
							[EPS for quarter and nine months ended is not annualised]						
3.07	1.33	3.66	25.94	27.59	48.54	a	Basic [₹] - After exceptional items	2.36	2.32	1.97	5.93	(0.11)	2.00
3.07	1.33	3.66	26.39	27.59	48.54	b	Basic [₹] - Before exceptional items	2.36	2.32	1.97	5.93	(0.11)	2.00
3.07	1.33	3.66	25.94	27.59	48.54	c	Diluted [₹] - After exceptional items	2.36	2.32	1.97	5.93	(0.11)	2.00
3.07	1.33	3.66	26.39	27.59	48.54	d	Diluted [₹] - Before exceptional items	2.36	2.32	1.97	5.93	(0.11)	2.00

**Notes :**

- The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on February 2, 2023. The Statutory Auditors of the Company have carried out Limited Review of the aforesaid results.
- The Company operates in one segment, namely "Consumer Products".
- Due to seasonality of some of the Company's products, Company's Revenues and Profits are skewed in favour of the first and last quarters of the financial year. Hence the performance of these quarters is not representative and cannot be generalised for other quarters.
- As a part of manufacturing and supply chain network optimisation and to make manufacturing operations leaner and agile to the consumer needs, the Company (and its subsidiaries) has conducted a strategic review of its manufacturing footprint. In view of the same, the Board of Directors of Zydus Wellness Product Limited, a wholly owned subsidiary Company, at their meeting held on June 17, 2022, passed a resolution to cease the operations of Sitarganj manufacturing facility. The Company does not anticipate any material effect due to this decision and the expenses incurred so far in connection with the cessation of Sitarganj facility have been classified as Exceptional items in the above results.
- Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

By Order of the Board,  
For Zydus Wellness Limited,



Dr. Sharvil P. Patel  
Chairman  
DIN: 00131995

February 2, 2023

Listing Department

**Code: 531 335**

**BSE LIMITED**

P J Towers, Dalal Street, Fort,

Mumbai-400 001

Listing Department

**Code: ZYDUSWELL**

**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, Bandra Kurla Complex,

Bandra (E),

Mumbai-400 051

Sub: **Outcome of Board Meeting**

Dear Sir / Madam,

The Board of Directors at their meeting held today i.e. February 2, 2023, based on the recommendations of Audit Committee, approved the unaudited financial results for the quarter and nine months ended on December 31, 2022.

In this regard, please find enclosed the following:

1. the unaudited financial results (standalone and consolidated) for the quarter and nine months ended on December 31, 2022, reviewed by the Audit Committee and taken on record by the Board of Directors, today i.e. February 2, 2023 pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the **Listing Regulations**”).
2. the Limited Review Reports of M/s. Mukesh M. Shah & Co., Chartered Accountants and the Statutory Auditors of the Company certifying the limited review of the unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months ended on December 31, 2022 pursuant to regulation 33 of the Listing Regulations.

**Zydus Wellness Limited**

(a subsidiary of Zydus Lifesciences Limited)

**Regd. Office:** ‘Zydus Corporate Park’, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India.

**Phone No.:** +91-79-71800000; **Website:** [www.zyduswellness.com](http://www.zyduswellness.com)

**CIN:** L15201GJ1994PLC023490



The Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed until Sunday, February 5, 2023 and shall re-open for trading for all Directors and Designated Persons on and from Monday, February 6, 2023.

The Board meeting commenced at 11:30 a.m. and concluded at 12:30 p.m.

Please find the same in order.

Thanking you,

Yours faithfully,

For, **ZYDUS WELLNESS LIMITED**

NANDISH  
PRADIP JOSHI

Digitally signed by NANDISH  
PRADIP JOSHI  
Date: 2023.02.02 12:39:30  
+05'30'

**NANDISH P. JOSHI**  
**COMPANY SECRETARY**

**Encl.:** As above

**Zydus Wellness Limited**

(a subsidiary of Zydus Lifesciences Limited)

**Regd. Office:** 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad – 382481, India.

**Phone No.:** +91-79-71800000; **Website:** [www.zyduswellness.com](http://www.zyduswellness.com)

**CIN:** L15201GJ1994PLC023490

**Statement of Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2022**

₹ in Lakhs						Sr. No.	Particulars	₹ in Lakhs					
CONSOLIDATED								COMPANY					
Quarter Ended		Nine Months Ended		Year Ended				Quarter Ended		Nine Months Ended		Year Ended	
December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022	December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022		
		[Unaudited]			[Audited]			[Unaudited]			[Audited]		
						1	<b>Income</b>						
						a	Revenue from operations						
41,296	42,677	38,493	1,53,271	1,35,327	1,98,846	i	Sales	5,523	5,920	6,194	16,841		
262	270	316	910	1,605	2,064	ii	Other operating income	849	802	892	2,433		
41,558	42,947	38,809	1,54,181	1,36,932	2,00,910		<b>Total Revenue from operations</b>	6,372	6,722	7,086	19,274		
84	135	269	414	844	1,040		Other income	334	289	370	994		
41,642	43,082	39,078	1,54,595	1,37,776	2,01,950		<b>Total Income</b>	6,706	7,011	7,456	20,268		
						2	<b>Expenses</b>						
26,603	20,916	21,432	72,531	54,620	88,494	a	Cost of materials consumed	4,227	4,320	3,902	12,698		
1,478	1,376	837	6,108	4,890	9,463	b	Purchases of stock-in-trade	-	-	-	-		
(4,757)	2,057	(2,196)	895	7,085	80	c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(138)	139	704	84		
3,509	4,363	3,820	12,381	12,349	16,356	d	Employee benefits expense	619	806	796	2,171		
384	294	642	1,092	1,953	2,551	e	Finance costs	55	1	54	101		
588	643	584	1,835	1,754	2,362	f	Depreciation and amortisation expense	74	106	70	252		
4,426	5,169	5,317	19,212	16,991	23,475	g	Advertisement and promotion expense	-	-	222	-		
7,480	7,440	6,370	23,797	20,672	28,567	h	Other expenses	429	208	452	1,296		
39,711	42,258	36,806	1,37,851	1,20,314	1,71,348		<b>Total expenses</b>	5,266	5,580	6,200	16,602		
1,931	824	2,272	16,744	17,462	30,602	3	<b>Profit/ [Loss] before exceptional items and tax [1-2]</b>	1,440	1,431	1,256	3,666		
-	-	-	291	-	-	4	Exceptional items [Refer Note 4]	-	-	-	(71)		
1,931	824	2,272	16,453	17,462	30,602	5	<b>Profit/ [Loss] before tax [3-4]</b>	1,440	1,431	1,256	3,666		
-	-	-	-	-	-	6	<b>Tax expense</b>						
(25)	(23)	(58)	(51)	(95)	(285)	a	Current tax	-	-	-	-		
(25)	(23)	(58)	(51)	(95)	(285)	b	Deferred tax	(63)	(47)	-	(110)		
1,956	847	2,330	16,504	17,557	30,887		<b>Total tax expenses</b>	(63)	(47)	-	(110)		
(7)	(17)	(125)	(49)	(377)	(101)	7	<b>Net Profit/ [Loss] [5-6]</b>	1,503	1,478	1,256	3,776		
-	8	-	28	7	20	8	<b>Other Comprehensive Income [OCI]</b>						
(7)	(9)	(125)	(21)	(370)	(81)	a	Items that will not be reclassified to profit or loss [net of tax]	(8)	(74)	(11)	(81)		
1,949	838	2,205	16,483	17,187	30,806	b	Items that will be reclassified to profit or loss [net of tax]	-	-	-	-		
1,949	838	2,205	16,483	17,187	30,806		<b>Total Other Comprehensive Income [net of tax]</b>	(8)	(74)	(11)	(81)		
6,363	6,363	6,363	6,363	6,363	4,78,040	9	<b>Total Comprehensive Income [7+8]</b>	1,495	1,404	1,245	3,695		
						10	<b>Total Comprehensive Income attributable to:</b>						
						a	Owners of the company	1,495	1,404	1,245	3,695		
						11	Paid-up equity share capital [Face Value ₹ 10 each]	6,363	6,363	6,363	6,363		
						12	Reserve excluding Revaluation Reserve	-	-	-	-		
						13	<b>Earnings per share [EPS]</b>						
							[EPS for quarter and nine months ended is not annualised]						
3.07	1.33	3.66	25.94	27.59	48.54	a	Basic [₹] - After exceptional items	2.36	2.32	1.97	5.93		
3.07	1.33	3.66	26.39	27.59	48.54	b	Basic [₹] - Before exceptional items	2.36	2.32	1.97	5.93		
3.07	1.33	3.66	25.94	27.59	48.54	c	Diluted [₹] - After exceptional items	2.36	2.32	1.97	5.93		
3.07	1.33	3.66	26.39	27.59	48.54	d	Diluted [₹] - Before exceptional items	2.36	2.32	1.97	5.93		

**Notes :**

- The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on February 2, 2023. The Statutory Auditors of the Company have carried out Limited Review of the aforesaid results.
- The Company operates in one segment, namely "Consumer Products".
- Due to seasonality of some of the Company's products, Company's Revenues and Profits are skewed in favour of the first and last quarters of the financial year. Hence the performance of these quarters is not representative and cannot be generalised for other quarters.
- As a part of manufacturing and supply chain network optimisation and to make manufacturing operations leaner and agile to the consumer needs, the Company (and its subsidiaries) has conducted a strategic review of its manufacturing footprint. In view of the same, the Board of Directors of Zydus Wellness Product Limited, a wholly owned subsidiary Company, at their meeting held on June 17, 2022, passed a resolution to cease the operations of Sitarganj manufacturing facility. The Company does not anticipate any material effect due to this decision and the expenses incurred so far in connection with the cessation of Sitarganj facility have been classified as Exceptional items in the above results.
- Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

By Order of the Board,  
For Zydus Wellness Limited,



Dr. Sharvil P. Patel  
Chairman  
DIN: 00131995

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

To,  
The Board of Directors,  
Zydus Wellness Limited

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zydus Wellness Limited** ['the Company'], for the quarter and nine months ended on December 31, 2022 ['the Statement'] attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
2. This statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad

Date: February 2, 2023

UDIN: 23030190BGYYFI7980



For Mukesh M. Shah & Co  
Chartered Accountants  
Firm Regn. No. 106625W

Mukesh M. Shah  
Partner  
Membership No. 030190

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

To,  
The Board of Directors,  
Zydus Wellness Limited

1. We have reviewed the accompanying statement of Consolidated unaudited financial results of **Zydus Wellness Limited** [‘the Parent’] and its subsidiaries [the Parent and its subsidiaries together referred to as ‘the Group’] for the quarter and nine months ended on December 31, 2022 [‘the Statement’] attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
2. This statement, which is the responsibility of the Parent’s Management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of Parent’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the financial results of the following entities:
  - a) Parent Company
    - i) Zydus Wellness Limited
  - b) Subsidiary Companies
    - i) Zydus Wellness Products Limited
    - ii) Liva Nutritions Limited
    - iii) Liva Investments Limited
    - iv) Zydus Wellness International DMCC
    - v) Zydus Wellness (BD) Pvt Limited
5. Based on our review conducted and procedures performed as stated in Paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind-AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



# MUKESH M. SHAH & CO.

CHARTERED ACCOUNTANTS

6. We did not review the interim financial information of 3 subsidiaries included in the consolidated unaudited financial results; whose interim financial information reflect [the figures reported below are before giving effect to consolidation adjustments] total income of ₹ 40,475 Lakhs and ₹ 1,51,956 Lakhs for the quarter and nine months ended December 31, 2022 respectively, total net loss after tax of ₹ 5,853 Lakhs and ₹ 10,068 Lakhs for the quarter and nine months ended December 31, 2022 respectively and total comprehensive Income of ₹ (5,852) Lakhs and ₹ (10,036) Lakhs for the quarter and nine months ended December 31, 2022 respectively, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the reports of the other auditors.

Our conclusion on the Statement is not modified in respect of these matters.

7. The consolidated financial results also include the financial information of 2 subsidiaries included in the consolidated unaudited financial results; whose interim financial information reflect [the figures reported below are before giving effect to consolidation adjustments] total income of ₹ 1,736 Lakhs and ₹ 4,081 Lakhs for the quarter and nine months ended December 31, 2022 respectively, total net loss after tax of ₹ 280 Lakhs and ₹ 560 Lakhs for the quarter and nine months ended December 31, 2022 respectively and total comprehensive Income of ₹ (280) Lakhs and ₹ (560) Lakhs for the quarter and nine months ended December 31, 2022 respectively, as considered in the Statement. No limited review of these financial information has been carried out by the auditors of the respective subsidiaries; however, according to the information and explanations given to us by the Management, these interim financial information have been subjected to review by the management of the respective subsidiaries. This interim financial information is not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information as certified by the management.

Place: Ahmedabad

Date: February 2, 2023

UDIN: 23030190BGYYFH7944



For Mukesh M. Shah & Co  
Chartered Accountants  
Firm Regn. No. 106625W

Mukesh M. Shah  
Partner  
Membership No. 030190